Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × belzutifan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 21 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 4 Pheochromocytoma 2 Paraganglioma 2 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Trastuzumab 517 Paclitaxel 492 Cyclophosphamide 474 Docetaxel 421 Capecitabine 355 Letrozole 306 Fulvestrant 272 Doxorubicin 250 Carboplatin 238 Tamoxifen 226 Anastrozole 185 Radiotherapy 180 exemestane 179 Epirubicin 177 Bevacizumab 169 Lapatinib 150 Vinorelbine 147 Gemcitabine 147 pertuzumab 143 pembrolizumab 143 palbociclib 131 Exercise 114 Fluorouracil 104 Albumin-Bound Paclitaxel 104 Magnetic Resonance Spectroscopy 101 eribulin 97 130-nm albumin-bound paclitaxel 91 Everolimus 89 Taxes 83 Cisplatin 81

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06428396 2025-12-26

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡